Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.

CONCLUSIONS: Among second-line TKI-treated CML patients, dasatinib patients had significantly higher adherence and lower discontinuation rates compared with patients receiving second-line nilotinib. PMID: 25278323 [PubMed - in process]
Source: Journal of Managed Care Pharmacy - Category: Drugs & Pharmacology Tags: J Manag Care Pharm Source Type: research